scispace - formally typeset
J

Julian Grosskreutz

Researcher at University of Jena

Publications -  179
Citations -  6657

Julian Grosskreutz is an academic researcher from University of Jena. The author has contributed to research in topics: Amyotrophic lateral sclerosis & Medicine. The author has an hindex of 41, co-authored 152 publications receiving 5038 citations. Previous affiliations of Julian Grosskreutz include University of Sheffield & University of Graz.

Papers
More filters
Journal ArticleDOI

Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis

Wouter van Rheenen, +187 more
- 01 Sep 2016 - 
TL;DR: Evidence of ALS being a complex genetic trait with a polygenic architecture is established and the SNP-based heritability is estimated at 8.5%, with a distinct and important role for low-frequency variants (frequency 1–10%).
Journal ArticleDOI

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model

TL;DR: An externally validated model is developed to predict survival without tracheostomy and non-invasive ventilation for more than 23 h per day in European patients with ALS and could be applied to individualised patient management, counselling, and future trial design.
Journal ArticleDOI

The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons

TL;DR: The chemotherapeutic oxaliplatin causes a sensory-motor neuropathy with predominantly hyperpathic symptoms and the mechanism underlying this hyperexcitability was investigated using rat sensory nerve preparations, dorsal root ganglia and hippocampal neurons, suggesting an interaction with voltage-gated Na(+) channels.
Journal ArticleDOI

Calcium dysregulation in amyotrophic lateral sclerosis

TL;DR: The hypothesis of a "toxic shift of Ca2+" within the endoplasmic reticulum-mitochondria Ca 2+ cycle (ERMCC) as a key mechanism in motor neuron degeneration is introduced, and molecular targets which may be of interest for future ERMCC modulating neuroprotective therapies are discussed.